Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Effect of Lipid Modification on Peripheral Arterial Disease After Endovascular Intervention ('The ELIMIT Trial')

Next Previous
Trial Profile

Effect of Lipid Modification on Peripheral Arterial Disease After Endovascular Intervention ('The ELIMIT Trial')

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 10 Feb 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ezetimibe (Primary) ; Niacin (Primary) ; Aspirin; Atorvastatin; Clopidogrel; Simvastatin
  • Indications Atherosclerosis
  • Focus Therapeutic Use
  • Acronyms ELIMIT Study

Most Recent Events

  • 11 Feb 2009 Planned end date changed from Jul 2010 to Aug 2010 as reported by ClinicalTrials.gov.
  • 26 Nov 2008 Status changed from recruiting to active, no longer recruiting as reported in ClinicalTrials.gov record.
  • 19 Jun 2008 New trial record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top